ATE370961T1 - Reinigung von antikörpern durch ionenaustauschchromatographie - Google Patents

Reinigung von antikörpern durch ionenaustauschchromatographie

Info

Publication number
ATE370961T1
ATE370961T1 AT02029009T AT02029009T ATE370961T1 AT E370961 T1 ATE370961 T1 AT E370961T1 AT 02029009 T AT02029009 T AT 02029009T AT 02029009 T AT02029009 T AT 02029009T AT E370961 T1 ATE370961 T1 AT E370961T1
Authority
AT
Austria
Prior art keywords
ion exchange
exchange chromatography
antibodies
purification
polypeptide
Prior art date
Application number
AT02029009T
Other languages
English (en)
Inventor
Carol D Basey
Greg S Blank
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22185093&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE370961(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE370961T1 publication Critical patent/ATE370961T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02029009T 1998-05-06 1999-05-03 Reinigung von antikörpern durch ionenaustauschchromatographie ATE370961T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8445998P 1998-05-06 1998-05-06

Publications (1)

Publication Number Publication Date
ATE370961T1 true ATE370961T1 (de) 2007-09-15

Family

ID=22185093

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02029009T ATE370961T1 (de) 1998-05-06 1999-05-03 Reinigung von antikörpern durch ionenaustauschchromatographie
AT02029008T ATE321066T1 (de) 1998-05-06 1999-05-03 Anti-her2 antikörperzusammensetzung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02029008T ATE321066T1 (de) 1998-05-06 1999-05-03 Anti-her2 antikörperzusammensetzung

Country Status (20)

Country Link
US (10) US6489447B1 (de)
EP (1) EP1075488B2 (de)
JP (6) JP4469933B2 (de)
KR (3) KR101036414B1 (de)
CN (6) CN101333244B (de)
AT (2) ATE370961T1 (de)
AU (1) AU760048B2 (de)
BR (1) BRPI9910332B8 (de)
CA (1) CA2329829C (de)
CY (1) CY1107000T1 (de)
DE (3) DE69930424T2 (de)
DK (2) DK1075488T4 (de)
ES (3) ES2292682T3 (de)
GE (1) GEP20104997B (de)
IL (4) IL139035A0 (de)
NZ (1) NZ507557A (de)
PT (2) PT1308456E (de)
SI (1) SI1308455T1 (de)
WO (1) WO1999057134A1 (de)
ZA (1) ZA200005879B (de)

Families Citing this family (297)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
NZ507557A (en) * 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
EP1500661A1 (de) 1998-06-01 2005-01-26 Genetech, Inc. Trennung von Protein-Monomeren von Aggregaten mittels Ionaustausch-Chromatographie
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
EP1280923A2 (de) * 2000-04-28 2003-02-05 Millennium Pharmaceuticals, Inc. 14094, ein angehörige der menschlichen trypsin-familie, und dessen verwendungen
US6790709B2 (en) * 2001-11-30 2004-09-14 Intel Corporation Backside metallization on microelectronic dice having beveled sides for effective thermal contact with heat dissipation devices
US7452539B2 (en) 2001-12-19 2008-11-18 Genentech, Inc. Stabilizing polypeptides which have been exposed to urea
FR2840695B1 (fr) * 2002-06-07 2004-10-08 Chevrillon Philippe Ind Procede de fabrication de ceintures d'impression
US7998705B2 (en) * 2002-08-06 2011-08-16 FUJIFILM Diosynth Biotechnologies U.S.A., Inc Increased dynamic binding capacity in ion exchange chromatography by addition of polyethylene glycol
HUE033623T2 (en) * 2002-09-11 2017-12-28 Genentech Inc protein purification
TWI476206B (zh) * 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
US8140164B2 (en) 2003-10-15 2012-03-20 Rmx, Llc Therapeutic diaphragm stimulation device and method
US8160711B2 (en) 2003-10-15 2012-04-17 Rmx, Llc Multimode device and method for controlling breathing
US9259573B2 (en) 2003-10-15 2016-02-16 Rmx, Llc Device and method for manipulating exhalation
US8467876B2 (en) 2003-10-15 2013-06-18 Rmx, Llc Breathing disorder detection and therapy delivery device and method
US8265759B2 (en) 2003-10-15 2012-09-11 Rmx, Llc Device and method for treating disorders of the cardiovascular system or heart
US7979128B2 (en) 2003-10-15 2011-07-12 Rmx, Llc Device and method for gradually controlling breathing
US8244358B2 (en) 2003-10-15 2012-08-14 Rmx, Llc Device and method for treating obstructive sleep apnea
US7970475B2 (en) 2003-10-15 2011-06-28 Rmx, Llc Device and method for biasing lung volume
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
JP2007520495A (ja) 2004-02-06 2007-07-26 ボロディー トーマス ユリウス 下痢型過敏性腸症候群におけるアミノサリチル酸の使用法
US20060234907A1 (en) * 2004-02-13 2006-10-19 Werner Gehringer Albumin solution and process for the production thereof
US7713629B2 (en) * 2004-03-26 2010-05-11 Florida State University Research Foundation Hydrophobic fluorinated polyelectrolyte complex films and associated methods
US9056125B2 (en) * 2004-05-17 2015-06-16 Florida State University Research Foundation, Inc. Films for controlled cell growth and adhesion
GT200500155A (es) * 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
DK1771482T3 (da) * 2004-07-22 2014-10-20 Genentech Inc HER2-antistofsammensætning
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2006063042A2 (en) * 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
CN102580084B (zh) 2005-01-21 2016-11-23 健泰科生物技术公司 Her抗体的固定剂量给药
MX2007009566A (es) * 2005-02-09 2009-02-16 Genentech Inc Inhibicion de la difusion de la her2 con antagonistas de la metaloproteasa de matriz.
EP1850874B1 (de) 2005-02-23 2013-10-16 Genentech, Inc. Verzögerung des krankheitsverlauf bei eierstockkrebspatienten durch pertuzumab
US7585955B2 (en) * 2005-03-03 2009-09-08 Florida State University Research Foundation, Inc Protein separation from a protein mixture
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
US7459542B2 (en) * 2005-03-10 2008-12-02 Florida State University Research Foundation, Inc. Separation of albumin from protein samples
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
TWI320788B (en) † 2005-05-25 2010-02-21 Hoffmann La Roche Method for the purification of antibodies
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US8921344B2 (en) 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
US7452872B2 (en) 2005-08-24 2008-11-18 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
CN102887955A (zh) 2006-04-05 2013-01-23 艾博特生物技术有限公司 抗体纯化
US20080038753A1 (en) * 2006-08-01 2008-02-14 Illumigen Biosciences, Inc. Pharmaceutical manufacturing methods
SI2061803T2 (sl) 2006-08-28 2023-01-31 Ares Trading S.A. Postopek za čiščenje proteinov, ki vsebujejo FC
WO2008025747A1 (en) * 2006-08-28 2008-03-06 Ares Trading S.A. Process for the purification of fc-fusion proteins
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
AU2007294731B2 (en) 2006-09-13 2014-04-17 Abbvie Inc. Cell culture improvements
US8280513B2 (en) 2006-12-22 2012-10-02 Rmx, Llc Device and method to treat flow limitations
RU2474585C2 (ru) * 2007-01-22 2013-02-10 Дженентек, Инк. Осаждение и очистка белков полиэлектролитами
SI2132573T1 (sl) 2007-03-02 2014-07-31 Genentech, Inc. Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3
US7960139B2 (en) 2007-03-23 2011-06-14 Academia Sinica Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
CN101679509A (zh) * 2007-06-01 2010-03-24 弗·哈夫曼-拉罗切有限公司 免疫球蛋白纯化
PL2171090T3 (pl) * 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
AU2012227163B2 (en) * 2007-10-30 2015-07-16 Genentech, Inc. Antibody purification by cation exchange chromatography
ES2533266T5 (es) * 2007-10-30 2018-04-18 Genentech, Inc. Purificación de anticuerpos mediante cromatografía de intercambio catiónico
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
KR101658247B1 (ko) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 모듈 인식 도메인을 통한 항체 표적화
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
DK2644194T3 (en) 2008-03-18 2017-07-03 Genentech Inc Combinations of an anti-HER2 antibody-drug conjugate and docetaxel
SG190572A1 (en) 2008-04-29 2013-06-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CA2726087A1 (en) 2008-06-03 2009-12-10 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
TW201006485A (en) 2008-06-03 2010-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
ES2442024T3 (es) 2008-07-15 2014-02-07 Academia Sinica Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
BRPI0823046B1 (pt) * 2008-08-14 2021-12-14 Genentech, Inc Método para purificar um anticorpo monoclonal de uma composição compreendendo o anticorpo monoclonal e pelo menos uma proteína de ovário de hamster chinês (chop)
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
AU2008221604B2 (en) * 2008-09-22 2010-04-22 Commonwealth Scientific And Industrial Research Organisation Temperature-responsive polymer particles in protein separation applications
JP5913980B2 (ja) 2008-10-14 2016-05-11 ジェネンテック， インコーポレイテッド 免疫グロブリン変異体及びその用途
BRPI0920572A8 (pt) 2008-10-20 2015-10-27 Abbott Lab Inativação viral durante a purificação dos anticorpos
NZ592095A (en) 2008-10-20 2013-01-25 Abbott Lab Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography
BRPI0919879A2 (pt) * 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
WO2010099186A1 (en) * 2009-02-25 2010-09-02 Merck Sharp & Dohme Corp. Her2 antibody compositions
MY152068A (en) 2009-03-20 2014-08-15 Genentech Inc Bispecific anti-her antibodies
EP2424875B1 (de) * 2009-04-29 2016-01-06 Bio-Rad Laboratories, Inc. Reinigung von immunkonjugaten
CN102421448A (zh) 2009-05-29 2012-04-18 霍夫曼-拉罗奇有限公司 Her2信号传导调控剂在表达her2的胃癌患者中
US20120177640A1 (en) 2009-07-24 2012-07-12 Josef Burg Optimizing the production of antibodies
AU2010275687A1 (en) 2009-07-24 2012-01-12 F. Hoffmann-La Roche Ag Stirrer system
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
DK2467399T3 (en) * 2009-08-20 2017-01-23 Baxalta Inc Purification of vWF for increased removal of non-lipid-enveloped viruses
WO2011028811A2 (en) 2009-09-01 2011-03-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
BR112012004054B1 (pt) 2009-10-01 2021-09-08 F. Hoffmann-La Roche Ag Método para produzir um anticorpo anti-her2
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US8304248B2 (en) * 2009-11-16 2012-11-06 Torres Anthony R Protein separation via ion-exchange chromatography and associated methods, systems, and devices
US8697844B2 (en) * 2009-11-24 2014-04-15 Novo Nordisk A/S Method of purifying pegylated proteins
US10087236B2 (en) 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
US11377485B2 (en) 2009-12-02 2022-07-05 Academia Sinica Methods for modifying human antibodies by glycan engineering
CN102770456B (zh) 2009-12-04 2018-04-06 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
US20110165155A1 (en) * 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
ES2982297T3 (es) 2009-12-18 2024-10-15 Novartis Ag Método de cromatografía de afinidad
US9556249B2 (en) 2010-02-18 2017-01-31 Genentech, Inc. Neuregulin antagonists and use thereof in treating cancer
US10338069B2 (en) 2010-04-12 2019-07-02 Academia Sinica Glycan arrays for high throughput screening of viruses
KR101152036B1 (ko) 2010-04-27 2012-06-08 (주)셀트리온 컬럼 순환 및 시료 연속주입법을 이용한 단백질 ａ 크로마토그래피 정제 방법
AU2011250970B2 (en) 2010-05-10 2016-12-15 Sinica, Academia Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
SG10201503899SA (en) * 2010-05-18 2015-06-29 Abbvie Inc Apparatus And Process Of Purification Of Proteins
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
KR101976853B1 (ko) 2010-05-25 2019-05-09 제넨테크, 인크. 폴리펩티드의 정제 방법
JP5956982B2 (ja) * 2010-05-27 2016-07-27 メルク・シャープ・エンド・ドーム・コーポレイション 改善された特性を有する抗体の製造方法
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
EP3252072A3 (de) 2010-08-03 2018-03-14 AbbVie Inc. Immunglobuline mit zweifacher variabler domäne und verwendungen davon
NZ604510A (en) 2010-08-17 2013-10-25 Csl Ltd Dilutable biocidal compositions and methods of use
JP2013539364A (ja) 2010-08-26 2013-10-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリンおよびその使用
WO2012029990A1 (ja) * 2010-09-01 2012-03-08 株式会社バイオマトリックス研究所 大腸がんマーカーに対する抗体
AU2011311673B2 (en) 2010-10-05 2015-09-17 F. Hoffmann-La Roche Ag Antibodies against human TWEAK and uses thereof
EP2627425A4 (de) * 2010-10-11 2014-11-05 Abbvie Inc Verfahren zur reinigung von proteinen
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
SG191071A1 (en) * 2010-12-08 2013-07-31 Amgen Inc Ion exchange chromatography in the presence of an amino acid
KR101574864B1 (ko) 2010-12-21 2015-12-11 에프. 호프만-라 로슈 아게 이소폼이 농축된 항체 제제 및 그의 제조 방법
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
AU2012222312B2 (en) 2011-03-03 2017-06-08 Arla Foods Amba Method for isolating osteopontin using feeds containing cmp or casein species
US9624294B2 (en) 2011-03-14 2017-04-18 Cellmid Limited Antibody recognizing N-domain of midkine
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
EP2714738B1 (de) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und ihre verwendungen
EP2718326B1 (de) 2011-06-13 2020-08-19 CSL Limited Antikörper gegen g-csfr und verwendungen davon
MX2014001766A (es) 2011-08-17 2014-05-01 Genentech Inc Anticuerpos de neuregulina y sus usos.
SG2014012470A (en) 2011-10-05 2014-06-27 Hoffmann La Roche Process for antibody g1 glycoform production
IL301603A (en) 2011-10-14 2023-05-01 Genentech Inc Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
AU2012327878A1 (en) 2011-10-28 2014-05-29 Patrys Limited PAT-LM1 epitopes and methods for using same
EP2773439A4 (de) * 2011-10-31 2015-07-01 Merck Sharp & Dohme Chromatographie-verfahren zur auflösung heterogener antikörperaggregate
HUE035685T2 (en) * 2011-11-02 2018-05-28 Hoffmann La Roche Overload and elute chromatography
BR112014012979A2 (pt) 2011-11-30 2020-10-20 Genentech, Inc. mutações erbb3 em câncer
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
US20130195851A1 (en) 2011-12-23 2013-08-01 Genentech, Inc. Articles of manufacture and methods for co-administration of antibodies
TW201333035A (zh) 2011-12-30 2013-08-16 Abbvie Inc 針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
US20130259867A1 (en) 2012-03-27 2013-10-03 Genentech, Inc. Diagnosis and treatments relating to her3 inhibitors
US10130714B2 (en) 2012-04-14 2018-11-20 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
EP2859017B1 (de) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Antikörper mit nichtnatürlichen stellenspezifischen aminosäureresten, verfahren zu deren herstellung und verfahren zu deren verwendung
WO2014004639A1 (en) * 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
WO2014031498A1 (en) 2012-08-18 2014-02-27 Academia Sinica Cell-permeable probes for identification and imaging of sialidases
AU2013305827A1 (en) 2012-08-21 2015-03-05 Academia Sinica Benzocyclooctyne compounds and uses thereof
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
TW202037609A (zh) 2012-11-01 2020-10-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
WO2014118685A2 (en) * 2013-01-29 2014-08-07 Dr. Reddy's Laboratories Limited Method of altering the acidic variant content of antibody
CN117843785A (zh) 2013-02-07 2024-04-09 Csl有限公司 Il-11r结合蛋白及其应用
AU2014226126B2 (en) 2013-03-08 2019-02-14 Genzyme Corporation Continuous purification of therapeutic proteins
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US10023608B1 (en) 2013-03-13 2018-07-17 Amgen Inc. Protein purification methods to remove impurities
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
EP2970379B1 (de) 2013-03-14 2019-05-01 EMD Millipore Corporation Verfahren zur erhöhung von proteinreinheit durch protein a-basierte chromatografie
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
MX368259B (es) 2013-04-16 2019-09-25 Genentech Inc Variantes de pertuzumab y su evaluacion.
TWI596107B (zh) 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
EP3013365B1 (de) 2013-06-26 2019-06-05 Academia Sinica Rm2-antigene und verwendung davon
EP3013347B1 (de) 2013-06-27 2019-12-11 Academia Sinica Glykankonjugate und verwendung davon
WO2015006555A2 (en) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
AU2014287044B2 (en) 2013-07-12 2020-02-06 Genentech, Inc. Elucidation of ion exchange chromatography input optimization
JP6486368B2 (ja) 2013-09-06 2019-03-20 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 改変されたグリコシル基を含む糖脂質を用いたヒトｉＮＫＴ細胞の活性化
JPWO2015041218A1 (ja) * 2013-09-17 2017-03-02 株式会社カネカ 新規抗体精製方法及びそれから得られる抗体（ＮｏｖｅｌＡｎｔｉｂｏｄｙＰｕｒｉｆｉｃａｔｉｏｎＭｅｔｈｏｄａｎｄＡｎｔｉｂｏｄｙｏｂｔａｉｎｅｄｔｈｅｒｅｆｒｏｍ）、並びに陽イオン交換基を用いた新規抗体精製法及びそれから得られる抗体（ＮｏｖｅｌＡｎｔｉｂｏｄｙＰｕｒｉｆｉｃａｔｉｏｎｍｅｔｈｏｄｕｓｉｎｇＣａｔｉｏｎＥｘｃｈａｎｇｅｒａｎｄＡｎｔｉｂｏｄｙｏｂｔａｉｎｅｄｔｈｅｒｅｆｒｏｍ）
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
SG10201811186XA (en) * 2013-10-18 2019-01-30 Novasep Process Purification of proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US10351592B2 (en) * 2013-10-30 2019-07-16 Celltrion, Inc. Method for separating antibody isoforms using cation exchange chromatography
CN104628846B (zh) * 2013-11-06 2019-12-06 三生国健药业（上海）股份有限公司 重组蛋白质的纯化方法
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
AU2015206370A1 (en) 2014-01-16 2016-07-07 Academia Sinica Compositions and methods for treatment and detection of cancers
US10150818B2 (en) 2014-01-16 2018-12-11 Academia Sinica Compositions and methods for treatment and detection of cancers
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
CN106103478B (zh) 2014-03-21 2020-04-03 豪夫迈·罗氏有限公司 抗体体内半寿期的体外预测
CN106415244B (zh) 2014-03-27 2020-04-24 中央研究院 反应性标记化合物及其用途
KR20160141857A (ko) 2014-04-25 2016-12-09 제넨테크, 인크. 트라스투주맙-mcc-dm1 및 퍼투주맙을 이용하는 초기 유방암의 치료방법
JP7093612B2 (ja) 2014-05-27 2022-06-30 アカデミア シニカ Ｂａｃｔｅｒｏｉｄｅｓ由来のフコシダーゼおよびそれを使用する方法
CN106661099A (zh) 2014-05-27 2017-05-10 中央研究院 抗her2醣抗体及其用途
CA2950415A1 (en) 2014-05-27 2015-12-03 Academia Sinica Anti-cd20 glycoantibodies and uses thereof
US10118969B2 (en) 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
WO2015184001A1 (en) 2014-05-28 2015-12-03 Academia Sinica Anti-tnf-alpha glycoantibodies and uses thereof
RU2017101727A (ru) * 2014-06-25 2018-07-25 ДжейЭйчЭл БИОТЕК, ИНК. Способы и реагенты для очистки белков
CN105315369B (zh) * 2014-07-25 2020-03-13 山东博安生物技术有限公司 利用阳离子交换层析纯化蛋白质
WO2016033245A1 (en) 2014-08-26 2016-03-03 Rmx, Llc Devices and methods for reducing intrathoracic pressure
TWI745275B (zh) 2014-09-08 2021-11-11 中央研究院 使用醣脂激活人類ｉＮＫＴ細胞
CN114181312A (zh) 2014-09-10 2022-03-15 豪夫迈·罗氏有限公司 半乳糖改造的免疫球蛋白1抗体
JP2021006540A (ja) * 2014-09-10 2021-01-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ガラクトース操作型免疫グロブリン１抗体
LT3191135T (lt) 2014-09-12 2020-11-25 Genentech, Inc. Anti-her2 antikūnai ir imunokonjugatai
MX2017003472A (es) 2014-09-17 2017-10-31 Genentech Inc Inmunoconjugados que comprenden anticuerpos anti-her2.
AU2015336946A1 (en) 2014-10-23 2017-04-13 La Trobe University Fn14-binding proteins and uses thereof
DK3215528T3 (da) 2014-11-06 2019-10-07 Hoffmann La Roche Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
KR101531479B1 (ko) * 2014-11-21 2015-06-26 세원셀론텍(주) 의료용 재료로 사용하기 위한 고농도 콜라겐 제조방법
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
WO2016094962A1 (en) 2014-12-19 2016-06-23 Monash University Il-21 antibodies
CN110655582B (zh) * 2015-01-08 2022-12-16 江苏康宁杰瑞生物制药有限公司 具有共同轻链的双特异性抗体或抗体混合物
ES2924394T3 (es) 2015-01-09 2022-10-06 Adalta Ltd Moléculas de unión a CXCR4
US9975965B2 (en) 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers
US10495645B2 (en) 2015-01-16 2019-12-03 Academia Sinica Cancer markers and methods of use thereof
WO2016118707A1 (en) * 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
JP6779887B2 (ja) 2015-01-24 2020-11-04 アカデミア シニカＡｃａｄｅｍｉａ Ｓｉｎｉｃａ 新規なグリカンコンジュゲートおよびその使用方法
WO2016149088A1 (en) * 2015-03-13 2016-09-22 Bristol-Myers Squibb Company Use of alkaline washes during chromatography to remove impurities
WO2016196373A2 (en) 2015-05-30 2016-12-08 Genentech, Inc. Methods of treating her2-positive metastatic breast cancer
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
CN108064246A (zh) 2015-06-15 2018-05-22 基因泰克公司 抗体和免疫结合物
TR201908138T4 (tr) 2015-07-07 2019-06-21 Hoffmann La Roche Bir anti-her2 antikoru ilaç konjügatı ve bir bcl-2 inhibitörü ile kombinasyon terapisi.
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
BR112018009881A2 (pt) * 2015-11-18 2018-11-13 Merck Patent Gmbh separação de proteína aperfeiçoada em cromatografia de troca iônica
JP2018537458A (ja) * 2015-11-18 2018-12-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 改善されたタンパク質分離のための逆ｐＨ塩勾配
AU2016361462B2 (en) 2015-11-27 2023-09-21 Csl Limited CD131 binding proteins and uses thereof
WO2017132615A1 (en) 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
CN109563161A (zh) 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂
EP3426693A4 (de) 2016-03-08 2019-11-13 Academia Sinica Verfahren zur modularen synthese von n-glykanen und anordnungen davon
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
KR102470282B1 (ko) 2016-07-15 2022-11-24 에프. 호프만-라 로슈 아게 Ｐｅｇ화 에리트로포이에틴을 정제하기 위한 방법
CA3034057A1 (en) 2016-08-22 2018-03-01 CHO Pharma Inc. Antibodies, binding fragments, and methods of use
EP3504234A4 (de) 2016-09-29 2020-12-02 Beijing Hanmi Pharmaceutical Co., Ltd. Heterodimere immunglobulinkonstrukte und herstellungsverfahren dafür
WO2018085513A1 (en) 2016-11-04 2018-05-11 Genentech, Inc. Treatment of her2-positive breast cancer
KR102247704B1 (ko) * 2016-11-18 2021-05-03 북경한미약품 유한공사 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법
EP3562844A1 (de) 2016-12-28 2019-11-06 Genentech, Inc. Behandlung von fortgeschrittenem her2-exprimierendem krebs
TW202508629A (zh) 2017-01-17 2025-03-01 美商建南德克公司 皮下her2抗體調配物
PT3589661T (pt) 2017-03-02 2024-01-29 Genentech Inc Tratamento com adjuvante de cancro da mama positivo para her2
WO2018200505A1 (en) 2017-04-24 2018-11-01 Genentech, Inc. Erbb2/her2 mutations in the transmbrane or juxtamembrane domain
EP4512469A3 (de) 2017-09-11 2025-05-21 Monash University Bindung von proteinen an den menschlichen thrombinrezeptor par4
CN107602702A (zh) 2017-09-22 2018-01-19 生标（上海）医疗器械科技有限公司 一种同时靶向人p185和血管内皮生长因子的抗体及其应用
CN108101987A (zh) * 2017-11-17 2018-06-01 安徽未名生物医药有限公司 一种重组抗TNF-α全人源单克隆抗体的纯化方法
US20210179721A1 (en) 2017-11-29 2021-06-17 Csl Limited Method of treating or preventing ischemia-reperfusion injury
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
JP7840636B2 (ja) 2018-04-02 2026-04-06 アムジェン インコーポレイテッド エレヌマブ組成物及びその使用
SG11202007961QA (en) 2018-04-13 2020-09-29 Hoffmann La Roche Her2-targeting antigen binding molecules comprising 4-1bbl
US20210340279A1 (en) 2018-08-31 2021-11-04 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
AU2019332764B2 (en) 2018-08-31 2025-05-29 Genzyme Corporation Sterile chromatography resin and use thereof in manufacturing processes
ES2932432T3 (es) 2018-10-15 2023-01-19 Hoffmann La Roche Métodos de tratamiento del cáncer de mama residual con trastuzumab emtansina
CN111196856A (zh) 2018-11-19 2020-05-26 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体
JP7301155B2 (ja) 2019-04-12 2023-06-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト リポカリンムテインを含む二重特異性抗原結合分子
WO2020234742A1 (en) 2019-05-20 2020-11-26 Lupin Limited Granulocyte colony stimulating factor purification
US20200390899A1 (en) 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
US11266838B1 (en) 2019-06-21 2022-03-08 Rmx, Llc Airway diagnostics utilizing phrenic nerve stimulation device and method
EP3996828A4 (de) * 2019-07-09 2023-09-06 Tanvex Biopharma Usa, Inc. Temperaturgesteuerte reinigung von granulozyten-kolonie stimulierendem faktor
US20220267751A1 (en) 2019-07-12 2022-08-25 Monash University Methods for making recombinant protein
CN110339209B (zh) * 2019-07-18 2023-06-06 上海泰坦科技股份有限公司 一种去甲状腺结合蛋白的小牛血清的制备方法
US20220313835A1 (en) 2019-09-03 2022-10-06 Bolt Biotherapeutics, Inc. Aminoquinoline compounds, immunoconjugates, and uses thereof
US20220347310A1 (en) 2019-09-30 2022-11-03 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
EP4045917A1 (de) * 2019-10-14 2022-08-24 Pierce Biotechnology, Inc. Peptidreinigungsformulierungen und -verfahren
TWI857167B (zh) 2019-10-25 2024-10-01 美商博特生物治療公司 噻吩并氮呯免疫結合物及其用途
EP4051714A4 (de) 2019-10-28 2023-11-22 Monash University Antikörper zum binden von plasmin
EP4058024A1 (de) 2019-11-15 2022-09-21 Seagen Inc. Verfahren zur behandlung von her2-positivem brustkrebs mit tucatinib in kombination mit einem anti-her2-antikörper-wirkstoff-konjugat
WO2021119761A1 (en) 2019-12-20 2021-06-24 Hudson Institute of Medical Research Cxcl10 binding proteins and uses thereof
CN115362270A (zh) 2020-01-29 2022-11-18 得克萨斯州大学系统董事会 Egfr/her2酪氨酸激酶抑制剂和/或her2/her3抗体在具有nrg1融合的癌症的治疗中的用途
JP7777533B2 (ja) 2020-01-29 2025-11-28 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｎｒｇ１融合体を有するがんの治療のためのポジオチニブの使用
US20230293716A1 (en) 2020-05-08 2023-09-21 Bolt Biotherapeutics, Inc. Elastase-substrate, peptide linker immunoconjugates, and uses thereof
US12583929B2 (en) 2020-06-04 2026-03-24 CSL Innovation Pty Ltd Method of treating acute respiratory distress syndrome
AU2021295549A1 (en) 2020-06-23 2022-11-24 F. Hoffmann-La Roche Ag Agonistic CD28 antigen binding molecules targeting Her2
US20230256110A1 (en) * 2020-06-24 2023-08-17 Astrazeneca Uk Limited Combination of antibody-drug conjugate and atm inhibitor
JP2023532122A (ja) 2020-06-29 2023-07-26 ジェネンテック， インコーポレイテッド ペルツズマブにトラスツズマブを加えた固定用量配合剤
JP2023533813A (ja) 2020-07-14 2023-08-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 一定用量配合剤のアッセイ
EP4182475A2 (de) 2020-07-17 2023-05-24 Onena Medicines S.L. Antikörper gegen linksprotein
JP2022023813A (ja) * 2020-07-27 2022-02-08 ファイザー・インク 組換え生産されたｒｓｖタンパク質の精製方法における陰イオン交換クロマトグラフィー用洗浄溶液の改良
JP2022023814A (ja) * 2020-07-27 2022-02-08 ファイザー・インク 組換え生産された三量体型のｒｓｖタンパク質の精製方法
IL300316A (en) 2020-08-13 2023-04-01 Bolt Biotherapeutics Inc Immune conjugates of pyrazolozapines and their uses
CN112430252B (zh) * 2020-11-13 2022-09-02 宜昌东阳光长江药业股份有限公司 一种提高目标蛋白回收率的层析方法
CN116897054A (zh) 2020-12-11 2023-10-17 博尔特生物治疗药物有限公司 抗her2免疫缀合物及其用途
KR20230118587A (ko) 2020-12-11 2023-08-11 제넨테크, 인크. Her2 암 치료를 위한 병용 요법
CA3200056A1 (en) 2020-12-11 2022-06-16 Shelley Erin ACKERMAN Anti-her2 immunoconjugates, and uses thereof
CN117769439A (zh) 2021-03-26 2024-03-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂卓免疫缀合物及其用途
CN117940168A (zh) 2021-03-26 2024-04-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
US20250188136A1 (en) 2021-04-01 2025-06-12 Vestaron Corporation Av3 mutant polypeptides for pest control
CN113769794B (zh) * 2021-07-06 2024-04-05 沁浩膜技术(厦门)有限公司 一种连续脱除胞磷胆碱钠中杂质的离子交换系统及方法
JP2024539993A (ja) 2021-10-29 2024-10-31 ボルト バイオセラピューティクス、インコーポレーテッド システイン変異抗体を含むｔｌｒアゴニスト免疫複合体、及びその使用
TW202337494A (zh) 2021-11-16 2023-10-01 美商建南德克公司 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物
WO2023122805A1 (en) 2021-12-20 2023-06-29 Vestaron Corporation Sorbitol driven selection pressure method
CN114230641B (zh) * 2021-12-29 2024-03-26 内蒙古必威安泰生物科技有限公司 一种去除口蹄疫抗原液中内毒素的方法
EP4499673A1 (de) 2022-03-30 2025-02-05 Vestaron Corporation Kombinationen aus av3-mutanten polypeptiden und bt toxinen zur schädlingsbekämpfung
US20260013513A1 (en) 2022-05-18 2026-01-15 Vestaron Corporation Pesticidal actx peptide variants
WO2023245100A1 (en) 2022-06-17 2023-12-21 Vestaron Corporation Antimicrobial ncr13 variant peptides
WO2024026406A2 (en) 2022-07-29 2024-02-01 Vestaron Corporation Next Generation ACTX Peptides
EP4573125A1 (de) 2022-08-18 2025-06-25 Immunocore Limited Multidomänenbindende moleküle
CN120077068A (zh) 2022-08-18 2025-05-30 英美偌科有限公司 多结构域结合分子
IL318933A (en) 2022-08-18 2025-04-01 Immunocore Ltd Multi-functional binding molecules
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
WO2024146951A1 (en) 2023-01-06 2024-07-11 Immunocore Limited Binding molecules against a prame peptide-hla complex
WO2024146936A1 (en) 2023-01-06 2024-07-11 Immunocore Limited Binding molecules against a piwil1 peptide-hla complex
WO2024173384A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
GB202306345D0 (en) 2023-04-28 2023-06-14 Immunocore Ltd Binding molecules
IL325176A (en) 2023-07-05 2026-02-01 CSL Innovation Pty Ltd Methods for treating or preventing a complication of sickle cell disease
WO2025094054A1 (en) 2023-11-01 2025-05-08 Immunocore Limited Method for purifying small multi-domain proteins
WO2025122745A1 (en) 2023-12-05 2025-06-12 Genentech, Inc. Combination therapies for treatment of her2 cancer
WO2025171411A1 (en) 2024-02-09 2025-08-14 Herophilus, Inc. Compositions and methods related to modulating macrophage migration inhibitory factor (mif)-cd74 signaling and related treatments for neuroinflammatory conditions
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof
WO2026050214A1 (en) 2024-08-27 2026-03-05 Bolt Biotherapeutics, Inc. Anti-claudin, tlr agonist immunoconjugates and uses thereof
WO2026055185A1 (en) 2024-09-04 2026-03-12 Bolt Biotherapeutics, Inc. Sting agonist immunoconjugates and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3070041D1 (en) * 1979-12-13 1985-03-07 Ciba Geigy Ag Optical brighteners from bistyryl benzene, process for their preparation and their use
US4511213A (en) * 1981-12-24 1985-04-16 Kokusai Denshin Denwa Kabushiki Kaisha Coding method for multilevel-gradated picture signal
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US5169774A (en) 1984-02-08 1992-12-08 Cetus Oncology Corporation Monoclonal anti-human breast cancer antibodies
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
WO1986002068A1 (fr) * 1984-09-26 1986-04-10 Takeda Chemical Industries, Ltd. Separation mutuelle de proteines
US5196323A (en) 1985-04-27 1993-03-23 Boehringer Ingelheim International Gmbh Process for preparing and purifying alpha-interferon
US5525338A (en) * 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
CA1283072C (en) * 1986-12-01 1991-04-16 Timothy Durance Process for the isolation and separation of lysozyme and avidin from eggwhite
EP0289129A3 (de) † 1987-03-26 1990-10-10 Repligen Corporation Herstellung von hochgereinigtem Protein A
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5451662A (en) * 1987-10-23 1995-09-19 Schering Corporation Method of purifying protein
US5118796A (en) 1987-12-09 1992-06-02 Centocor, Incorporated Efficient large-scale purification of immunoglobulins and derivatives
JP3040121B2 (ja) † 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
IT1219874B (it) * 1988-03-18 1990-05-24 Fidia Farmaceutici Utilizzazione del fattore di crescita nervoso umano e sue composizioni farmaceutiche
US5115101A (en) * 1988-06-08 1992-05-19 Miles Inc. Removal of protein A from antibody preparations
US5112951A (en) * 1989-07-28 1992-05-12 Hybritech Incorporated Separation of anti-metal chelate antibodies
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
US5110913A (en) 1990-05-25 1992-05-05 Miles Inc. Antibody purification method
EP1400536A1 (de) * 1991-06-14 2004-03-24 Genentech Inc. Verfahren zur Herstellung humanisierter Antikörper
US7018809B1 (en) 1991-09-19 2006-03-28 Genentech, Inc. Expression of functional antibody fragments
JPH05202098A (ja) * 1992-01-29 1993-08-10 Snow Brand Milk Prod Co Ltd 乳質原料から生理活性物質の製造法
US5279823A (en) * 1992-06-08 1994-01-18 Genentech, Inc. Purified forms of DNASE
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
DK38293D0 (da) † 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
DE59309332D1 (de) * 1993-12-27 1999-03-04 Rotkreuzstiftung Zentratrallab Verfahren zur Herstellung eines Konzentrates von Anti-D-Immunoglobulin G und pharmazeutische Zusammensetzung, die dieses enthält
US5429746A (en) * 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
DE4436910A1 (de) * 1994-10-15 1996-04-18 Behringwerke Ag Regenerierbare Festphase zur Durchführung spezifischer Bindereaktionen
GB9423454D0 (en) * 1994-11-21 1995-01-11 Allied Colloids Ltd Deinking processes and novel polymers for use in these
US5641870A (en) * 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
IL118201A (en) 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
US5714583A (en) † 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
ES2434840T3 (es) * 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JPH1042892A (ja) * 1996-08-01 1998-02-17 Higeta Shoyu Co Ltd タンパク質の回収精製法
AU729459B2 (en) * 1996-11-15 2001-02-01 Genentech Inc. Purification of neurotrophins
DE69738075T2 (de) 1996-11-27 2008-05-21 Genentech, Inc., South San Francisco Affinitätsreinigung von polypeptiden an einer protein a-matrix
DE19724054C2 (de) 1997-06-07 2002-09-12 Braun Gmbh Strahlungsthermometer und Schutzkappe dafür
NZ507557A (en) 1998-05-06 2003-10-31 Genentech Inc Protein purification by ion exchange chromatography
BR0114373A (pt) 2000-10-02 2004-02-17 Novo Nordisk As Célula hospedeira eucariótica, métodos para a produção de fvii e de fviia ou de suas variantes, de uma proteìna dependente de vitamina k e de uma célula hospedeira eucariótica produtora de fvii ou de seu análogo, vetor recombinante, fvii e fviia recombinante ou suas variantes, e, proteìna dependente de vitamina k recombinante
CN101818137A (zh) 2003-03-18 2010-09-01 诺和诺德医疗保健公司 生产含有gla残基的丝氨酸蛋白酶的方法

Also Published As

Publication number Publication date
DE69930424D1 (de) 2006-05-11
DE69907439T3 (de) 2014-01-02
CN100404547C (zh) 2008-07-23
ATE321066T1 (de) 2006-04-15
IL139035A (en) 2006-10-31
KR100960211B1 (ko) 2010-05-27
AU760048B2 (en) 2003-05-08
DK1075488T3 (da) 2003-08-18
JP5836905B2 (ja) 2015-12-24
PT1308455E (pt) 2006-08-31
CN1626547A (zh) 2005-06-15
BRPI9910332B8 (pt) 2021-05-25
EP1075488B1 (de) 2003-05-02
US20160376377A1 (en) 2016-12-29
NZ507557A (en) 2003-10-31
US20090220492A1 (en) 2009-09-03
AU3877799A (en) 1999-11-23
US6417335B1 (en) 2002-07-09
JP2010106023A (ja) 2010-05-13
JP4469933B2 (ja) 2010-06-02
ZA200005879B (en) 2001-10-22
PT1308456E (pt) 2007-12-03
CN1810292A (zh) 2006-08-02
US9249218B2 (en) 2016-02-02
KR20060081422A (ko) 2006-07-12
KR20010043323A (ko) 2001-05-25
CN1626548A (zh) 2005-06-15
WO1999057134A1 (en) 1999-11-11
JP2016028060A (ja) 2016-02-25
CN1299370A (zh) 2001-06-13
ES2198913T3 (es) 2004-02-01
SI1308455T1 (sl) 2006-08-31
US7531645B2 (en) 2009-05-12
GEP20104997B (en) 2010-06-10
DK1075488T4 (da) 2013-10-21
ES2198913T5 (es) 2013-11-18
KR101036414B1 (ko) 2011-05-23
US20030078388A1 (en) 2003-04-24
BR9910332A (pt) 2001-09-25
IL173183A (en) 2013-11-28
DE69936946T2 (de) 2008-05-15
HK1055307A1 (en) 2004-01-02
CY1107000T1 (el) 2012-09-26
CN1305896C (zh) 2007-03-21
IL228987A0 (en) 2013-12-31
IL139035A0 (en) 2001-11-25
JP2018140994A (ja) 2018-09-13
EP1075488A1 (de) 2001-02-14
CN103641885A (zh) 2014-03-19
DE69936946D1 (de) 2007-10-04
HK1055308A1 (en) 2004-01-02
US20140018523A1 (en) 2014-01-16
CN101333244A (zh) 2008-12-31
EP1075488B2 (de) 2013-08-07
IL173183A0 (en) 2006-06-11
CN101333244B (zh) 2013-12-18
CA2329829C (en) 2012-10-16
DE69930424T2 (de) 2006-12-14
JP2002513800A (ja) 2002-05-14
CN1260249C (zh) 2006-06-21
ES2292682T3 (es) 2008-03-16
BRPI9910332B1 (pt) 2016-10-25
DK1308456T3 (da) 2007-12-27
JP2013032365A (ja) 2013-02-14
JP5133962B2 (ja) 2013-01-30
US7074404B2 (en) 2006-07-11
DE69907439D1 (de) 2003-06-05
US6489447B1 (en) 2002-12-03
KR20100017967A (ko) 2010-02-16
DE69907439T2 (de) 2004-04-01
ES2261589T3 (es) 2006-11-16
JP2017149721A (ja) 2017-08-31
US6339142B1 (en) 2002-01-15
US20060182739A1 (en) 2006-08-17
US20050063972A1 (en) 2005-03-24
US20170226224A1 (en) 2017-08-10
CA2329829A1 (en) 1999-11-11

Similar Documents

Publication Publication Date Title
ATE370961T1 (de) Reinigung von antikörpern durch ionenaustauschchromatographie
EP1308456A3 (de) Reinigung von Antikörpern durch Ionenaustauschchromatographie
EP3388452A3 (de) Proteinreinigung
ATE425989T1 (de) Proteinreinigungsverfahren
ATE363491T1 (de) Reinigung von antikörpern durch protein a und ionenaustauschromatographie
DE68915675D1 (de) Verfahren zur Reinigung von Vitamin K-abhängigen Proteinen.
FR2666996B1 (fr) Methode de purification d'un aminoacide utilisant une resine echangeuse d'ions.
DK0746398T3 (da) Antistofrensning
DK1084146T3 (da) Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf
DK0828753T3 (da) A1/Fe-behandling af en proteinopløsning efterfulgt af membranopkoncentrering
ATE314391T1 (de) Methode zur reinigung von thrombopoietin
ATE328007T1 (de) Reinigung von fibrinogen aus flüssigkeiten mittels ausfällung und hydrophobischer- interaktion-chromatographie
EP0656419A4 (de) Verfahren zur hochreinigung von menschlichem serumalbumin.
ATE278705T1 (de) Verfahren zur reinigung von proteinen
DE69619137D1 (de) Verfahren zur reinigung von dimethylsulfoxyd (dmso)
ATE426611T1 (de) Verfahren zur reinigung eines kalziumionen- bindenden proteins
ATE351909T1 (de) Neue peptidfragmente zur reinigung von proteinen
DE69716106D1 (de) Trennung von proteinen durch kapillarelektrophorese mit aminosäure enthaltenden puffern
KR910011280A (ko) 알칼리성 포스파타제의 정제방법
ATE27987T1 (de) Adsorbens-zusammenstellung brauchbar zur korrosionsverminderung in auspuffanlagen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1308456

Country of ref document: EP